| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg | |||
| Other Sizes |
| Targets |
NIR-II light (1000-1700 nm) is the primary target for imaging. FD-1080 is designed as a passive fluorophore without a specific biomolecular target, used for labeling and tracking tissues or cells.
|
|---|---|
| ln Vitro |
Under continuous laser irradiation, FD-1080 exhibits superior photostability. When FD-1080 is combined with fetal bovine serum (FBS) to form FD-1080-FBS complexes, its quantum yield increases to 5.94% from 0.31%[1].
FD-1080 free acid is a fluorophore with both excitation and emission in the NIR-II region (Ex=1064 nm, Em=1080 nm). It exhibits enhanced photostability when subjected to sustained laser exposure. It is a fluorophore that can be used for in vivo imaging. |
| ln Vivo |
Compared to NIR excitation from 650 nm to 980 nm, the 1064 nm NIR-II excitation of FD-1080 is shown to have a higher tissue penetration depth and better imaging resolution. It was possible to obtain deeptissue and high-resolution in vivo imaging that could penetrate through intact skin, tissue, and skull for the left hindlimb vasculature, abdomen, and brain vessels. For both awake and anesthetized mice, FD-1080 measures the respiratory rate via dynamic imaging of the liver's respiratory craniocaudal motion[1].
There is no specific in vivo activity data available for this compound beyond its use as an imaging agent. In animal models, FD-1080 can be used for deep-tissue imaging of vasculature, lymph nodes, and tumors with high spatial resolution and deep tissue penetration. |
| Enzyme Assay |
A standard protocol involves dissolving FD-1080 free acid in a suitable solvent (e.g., PBS or saline with co-solvents like DMSO) and measuring its absorbance and fluorescence spectra using a spectrophotometer. The excitation and emission peaks should be confirmed at 1064 nm and 1080 nm, respectively.
|
| Cell Assay |
There is no specific cellular experiment protocol for a passive fluorophore. However, it can be loaded into cells via endocytosis or microinjection for intracellular tracking. A general protocol involves incubating cells with FD-1080-conjugated nanoparticles or antibodies for imaging of specific targets.
|
| Animal Protocol |
A typical in vivo imaging protocol involves intravenous injection of FD-1080 or its conjugates into a live animal model. After a suitable circulation time (e.g., 5 minutes to 2 hours), the animal is placed under an NIR-II imaging system equipped with a 1064 nm laser for excitation and a 1080 nm long-pass filter for emission detection.
|
| ADME/Pharmacokinetics |
General PK properties for small molecule fluorophores: After IV injection, FD-1080 is likely cleared through both renal and hepatobiliary routes depending on its formulation. Free acid forms may have relatively fast clearance. Conjugation to larger molecules (e.g., antibodies) can significantly prolong circulation time.
|
| Toxicity/Toxicokinetics |
General toxicity for NIR-II fluorophores is considered low. For FD-1080, no specific toxicity studies are reported. In general, NIR-II dyes are designed to have good biocompatibility with minimal toxicity at imaging doses. This product is for research use only.
|
| References | |
| Additional Infomation |
FD-1080 is a research tool for deep-tissue in vivo imaging. Its excitation and emission both fall within the NIR-II window (1000-1700 nm), enabling imaging depths of up to several centimeters in biological tissues. This product is for research use only.
|
| Molecular Formula |
C40H39CLN2O6S2
|
|---|---|
| Molecular Weight |
743.33046746254
|
| Exact Mass |
742.193
|
| CAS # |
1151888-25-3
|
| Related CAS # |
FD-1080;1151666-58-8
|
| PubChem CID |
168008650
|
| Appearance |
Brown to black solid powder
|
| LogP |
6.9
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
12
|
| Heavy Atom Count |
51
|
| Complexity |
1660
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C(C1=[N+](C2=CC=CC3=CC=CC1=C23)CCCCS([O-])(=O)=O)=CC1CCCC(=CC=C2N(C3=CC=CC4=CC=CC2=C34)CCCCS(O)(=O)=O)C=1Cl
|
| InChi Key |
NDZQFRYUXBSGNX-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C40H39ClN2O6S2/c41-40-30(20-22-34-32-16-6-10-28-12-8-18-36(38(28)32)42(34)24-1-3-26-50(44,45)46)14-5-15-31(40)21-23-35-33-17-7-11-29-13-9-19-37(39(29)33)43(35)25-2-4-27-51(47,48)49/h6-13,16-23H,1-5,14-15,24-27H2,(H-,44,45,46,47,48,49)
|
| Chemical Name |
4-[(2Z)-2-[(2E)-2-[2-chloro-3-[(E)-2-[1-(4-sulfobutyl)benzo[cd]indol-1-ium-2-yl]ethenyl]cyclohex-2-en-1-ylidene]ethylidene]benzo[cd]indol-1-yl]butane-1-sulfonate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.3453 mL | 6.7265 mL | 13.4530 mL | |
| 5 mM | 0.2691 mL | 1.3453 mL | 2.6906 mL | |
| 10 mM | 0.1345 mL | 0.6726 mL | 1.3453 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
